Tags

, , , , , , ,

Last week, IACP sent a letter to Food & Drug Administration (FDA) Commissioner Margaret Hamburg, MD, requesting information on not only why the FDA failed to take prompt action against New England Compounding Center (NECC) but also directly challenging their claims that the administration does not have adequate regulatory authority to halt illegal drug manufacturing.

“The IACP and its members strongly urge the FDA to explain the delays and inaction in the tragic case of the NECC, to identify which staff members were involved, to provide a timeline surrounding complaints about NECC, and to specify why decisions were made to let the company continue operating,” IACP Executive Vice President & CEO David G. Miller, RPh, stated in the letter. Click here to view the letter.

The Academy is also distributing a statement this afternoon via PR Newswire to all national news, trade and medical press. Click here to view the press release.

Please email IACP at iacpinfo@iacprx.org with any questions.

Advertisements